Nishisaki H, Yasutake K, Oya M, Nakashima T, Hasegawa H, Horita K, Yoshida R, Nakanishi Y, Abo K
Dept. of Gastroenterology, Hyogo Medical Center for Adults, Japan.
Gan To Kagaku Ryoho. 1996 Jun;23(7):923-8.
Three patients with chemotherapeutically pretreated metastatic gastric cancer were given MAC-VD therapy combining MMC, ADM, CDDP, Etoposide (VP-16) and 5'-DFUR. All were evaluable for their responses. Patients ranged in age from 49 to 61 years. Performance status scale (P.S.) grade 0 was two cases; and P.S. grade 1 was one case. The overall response rate, CR+PR, was 0+2/3 (66.7%). The response rate in the primary lesions was 0%, against 66.7% (2/3) in the liver, 100% (1/1) in the spleen, 100% (1/1) in the lung, and 0% in the abdominal lymph node metastasis. The chief manifestations of toxicity were hematologic, such as leukocytopenia, anemia and thrombocytopenia in 100% of the cases. Non-hematologic toxicity was seen in alopecia in 66.7%, diarrhea in 33.3%, fever in 33.3%, and pigmentation in 33.3%. Severe toxicity was not observed. From these data, the administration of MAC-VD therapy was considered tolerable and these data suggested that this therapy could be given as a second-line chemotherapy when initial treatment failed to obtain a response after a partial response.
三名接受过化疗预处理的转移性胃癌患者接受了MAC - VD疗法，该疗法联合使用了丝裂霉素（MMC）、阿霉素（ADM）、顺铂（CDDP）、依托泊苷（VP - 16）和去氧氟尿苷（5'-DFUR）。所有患者均对其反应进行了评估。患者年龄在49岁至61岁之间。体力状况评分（P.S.）为0级的有2例；P.S.为1级的有1例。总缓解率，即完全缓解（CR）+部分缓解（PR），为0 + 2/3（66.7%）。原发灶的缓解率为0%，而肝脏的缓解率为66.7%（2/3），脾脏为100%（1/1），肺为100%（1/1），腹部淋巴结转移灶为0%。毒性的主要表现为血液学方面，比如100%的病例出现白细胞减少、贫血和血小板减少。非血液学毒性方面，66.7%的病例出现脱发，33.3%出现腹泻，33.3%出现发热，33.3%出现色素沉着。未观察到严重毒性。根据这些数据，MAC - VD疗法的给药被认为是可耐受的，并且这些数据表明，当初始治疗未能获得反应或仅获得部分反应后，该疗法可作为二线化疗方案。
